<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.114261</article-id><article-id pub-id-type="publisher-id">ACM-41854</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210400000_37250682.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  1例儿童Gitelman综合征并矮小症的临床分析
  Clinical Analysis of a Child with Gitelman Syndrome and Short Stature
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>晨阳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>冯</surname><given-names>孝强</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学附属医院儿科二病区，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>04</month><year>2021</year></pub-date><volume>11</volume><issue>04</issue><fpage>1190</fpage><lpage>1196</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    Gitelman综合征(Gitelman syndrome, GS)又称家族性低钾低镁血症，是常染色体隐性遗传性肾小管失盐性疾病，临床表现为低血钾症、低氯性代谢性碱中毒、低镁血症、低尿钙、肾素–血管紧张素–醛固酮系统(Renin-angiotensin-aldosterone system, RAAS)激活，但血压正常或偏低。现将延安大学附属医院收治的1例以顽固低血钾症为临床表现的Gitelman综合征患儿的临床资料及诊疗过程，结合相关文献学习，做如下报道，旨在提高临床医师对该疾病的认识。
    Gitelman syndrome (Gitelman syndrome, GS), also known as familial hypokalemia and hypomagnesemia, is an autosomal recessive hereditary renal tubular salt loss disease with clinical manifestations of hypokalemia and hypochlorinated metabolic alkali Poisoning, hypomagnesemia, low urine calcium, renin-angiotensin-aldosterone system (Renin-angiotensin-aldosterone system, RAAS) is activated, but blood pressure is normal or low. The clinical data, the diagnosis and treatment process of a child with Gitelman syndrome with stubborn hypokalemia as clinical manifestations admitted to the Affiliated Hospital of Yan’an University, combined with relevant literature studies, are reported as follows, aiming to improve clinicians’ understanding of the disease. 
  
 
</p></abstract><kwd-group><kwd>低钾血症，Gitemlman综合征，SLC12A3基因, Hypokalemia</kwd><kwd> Gitemlman Syndrome</kwd><kwd> SLC12A3 Gene</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>Gitelman综合征(Gitelman syndrome, GS)又称家族性低钾低镁血症，是常染色体隐性遗传性肾小管失盐性疾病，临床表现为低血钾症、低氯性代谢性碱中毒、低镁血症、低尿钙、肾素–血管紧张素–醛固酮系统(Renin-angiotensin-aldosterone system, RAAS)激活，但血压正常或偏低。现将延安大学附属医院收治的1例以顽固低血钾症为临床表现的Gitelman综合征患儿的临床资料及诊疗过程，结合相关文献学习，做如下报道，旨在提高临床医师对该疾病的认识。</p></sec><sec id="s2"><title>关键词</title><p>低钾血症，Gitemlman综合征，SLC12A3基因</p></sec><sec id="s3"><title>Clinical Analysis of a Child with Gitelman Syndrome and Short Stature</title><p>Chenyang Wang<sup>*</sup>, Xiaoqiang Feng<sup>#</sup></p><p>Second Ward of Pediatrics, Affiliated Hospital of Yan’an University, Yan’an Shaanxi</p><p><img src="//html.hanspub.org/file/54-1572132x4_hanspub.png" /></p><p>Received: Mar. 19<sup>th</sup>, 2021; accepted: Apr. 19<sup>th</sup>, 2021; published: Apr. 26<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/54-1572132x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Gitelman syndrome (Gitelman syndrome, GS), also known as familial hypokalemia and hypomagnesemia, is an autosomal recessive hereditary renal tubular salt loss disease with clinical manifestations of hypokalemia and hypochlorinated metabolic alkali Poisoning, hypomagnesemia, low urine calcium, renin-angiotensin-aldosterone system (Renin-angiotensin-aldosterone system, RAAS) is activated, but blood pressure is normal or low. The clinical data, the diagnosis and treatment process of a child with Gitelman syndrome with stubborn hypokalemia as clinical manifestations admitted to the Affiliated Hospital of Yan’an University, combined with relevant literature studies, are reported as follows, aiming to improve clinicians’ understanding of the disease.</p><p>Keywords:Hypokalemia, Gitemlman Syndrome, SLC12A3 Gene</p><disp-formula id="hanspub.41854-formula36"><graphic xlink:href="//html.hanspub.org/file/54-1572132x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/54-1572132x8_hanspub.png" /> <img src="//html.hanspub.org/file/54-1572132x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>Gitelman综合征(Gitelman syndrome, GS)是一种常染色体隐性遗传病，也被称为家族性低钾低镁血症，1966年由Simon等人首次发现，其病因为编码肾远曲小管上皮细胞上噻嗪类敏感性Na/Cl协同转运(Na⁃Cl cotransporter, NCCT)基因突变所致，临床表现为低血钾症、低氯性代谢性碱中毒、低镁血症、低尿钙、肾素–血管紧张素–醛固酮系统(Renin-angiotensin-aldosterone system, RAAS)激活，但血压正常或偏低。经过许多病例报道，发现GS的发病率其实并不低，但大部分病例由于临床认识不足而误诊。本研究将我科收治的1例以顽固低血钾症为临床表现的Gitelman综合征患儿的临床资料及诊疗过程，结合相关文献学习，做如下报道，旨在提高临床医师对该疾病的认识，本研究已获得病人及家属的知情同意。</p></sec><sec id="s6"><title>2. 病历资料</title><p>现病史：患儿，男，4岁，以“呕吐4天”于2019年4月1日就诊于我院。呕吐无明显诱因，一吃即吐，呕吐物为胃内容物，无胆汁及血丝，为非喷射性，伴精神差，无发热、寒战，无腹痛、腹泻，无咯血、盗汗，无咳嗽、流涕，于当地医院住院治疗4天(具体不详)，患儿呕吐仍未见明显缓解，家属为求进一步诊治，来我院就诊，(2019.04.01本院门诊)血常规示：白细胞计数21.10 &#215; 10<sup>9</sup>/L，红细胞计数5.16 &#215; 10<sup>12</sup>/L，血红蛋白145 g/L，血小板计数525 &#215; 10<sup>9</sup>/L，中性粒细胞百分比89.50%，淋巴细胞百分比8.00%，中性粒细胞计数18.87 &#215; 10<sup>9</sup>/L，肾功电解质：钾1.4 mmol/L，钠144 mmol/L，氯111 mmol/L，钙2.46 mmol/L，尿素4.2 mmol/L，二氧化碳结合率18 mmol/L，肌酐33.0 umol/L，尿酸109 umol/L，葡萄糖10.80 mmol/L，心肌酶：LDH-L 295 u/L，α-HBDH 270 u/L，CK575 u/L，CK-MB 27.2 u/L，CRP：阴性。给予静滴碳酸氢钠、氯化钾、补液等对症治疗1天，患儿呕吐较前好转，(2019.04.02本院门诊)复查电解质示：K：1.90 mmol/L、Na：147 mmol/L，拟诊“呕吐待诊，低钾血症”收住入院。</p><p>既往史：体健，否认有麻疹、结核等传染病接触史，按期接种疫苗，否认药物过敏史，否认外伤及手术史。</p><p>个人史：患儿系第II胎II产，足月顺产，新法接生，出生体重：3.0 g。生时无异常，否认产伤及窒息史，患儿实际生活年龄：4岁10个月。</p><p>家族史：否认近亲婚配，否认家族中有遗传性、过敏性或急、慢性传染病史。</p><p>查体：体温37.0℃，脉搏80次/分，呼吸频率20次/分，身高：100 cm，体重11 kg，神志清，精神差，全身皮肤粘膜干燥，弹性差，眼窝凹陷，哭时无泪，听诊双肺呼吸音粗，未闻及干湿啰音。心率80次/分，心音可，律齐，各瓣膜区未闻及病理性杂音。腹软，未见肠型及蠕动波，肠鸣音活跃，腹肌无紧张，无压痛及反跳痛，肝脾肋下未及，神经系统查体未见异常。尿量明显减少，大便次数少。</p><p>入院后检查：血常规示：白细胞计数29.31 &#215; 10<sup>9</sup>/L (参考值5~12 &#215; 10<sup>9</sup>/L)，红细胞计数4.53 &#215; 10<sup>12</sup>/L (参考值4.2~5.2 &#215; 10<sup>12</sup>/L)，血红蛋白126 g/L (参考值120~140 g/L)，血小板计数449 &#215; 10<sup>9</sup>/L (参考值100~400 &#215; 10<sup>9</sup>/L)，中性粒细胞计数22.72 &#215; 10<sup>9</sup>/L (参考值1.8~6.3 &#215; 10<sup>9</sup>/L)，中性粒细胞百分比77.64% (参考值40%~75%)，淋巴细胞百分比17.94% (参考值20%~50%)，肝功：白蛋白42.4 g/L (参考值35~51 g/L)，谷丙转氨酶53 u/L (参考值0~40 u/L)，谷草转氨酶250 u/L (参考值0~40 u/L)，总胆红素26 umol/L (参考值1.7~17.1 umol/L)，直接胆红素10.1 umol/L (参考值0~6.8 umol/L)，间接胆红素15.9 umol/L (参考值1.7~10.2 umol/L)，心肌酶：乳清脱氢酶503 u/L (参考值95~200 U/L)，α羟丁酸脱氢酶447 u/L (90~182 u/L)，肌酸激酶6975 u/L (参考值44~200 U/L)，肌酸激酶同工酶106 u/L(参考值0~24 U/L)，血脂肪酶：187 U/L (0~190 U/L)，血清淀粉样蛋白18.9 mg/L (&lt;10 mg/L)，血、尿淀粉酶、PCT：均在正常范围；血气分析：PH 7.436，PCO<sub>2</sub> 27.2 mmHg，PO<sub>2</sub> 75.6 mmHg，cK<sup>+</sup> 1.6 mmol/L (参考值3.5~5.3 mmol/L)，cNa<sup>+</sup> 146 mmol/L (参考值137~147 mmol/L)，cCI<sup>−</sup> 117 mmol/L (参考值99~110 mmol/L)，cGlu 6.3 mmol/L，BE值= −5.9 mmol/L (−3.0~3.0 mmol/L)， HCO 3 − 20.5 mmol/L (参考值21.3~24.8 mmol/L)。心电图诊断：1) 窦性心律；2) 窦性心动过速；3) T波改变，请结合临床。CT检查报告示：肝脏、胆囊、胰腺、脾脏、双肾及扫描野内肠管CT平扫未见明显异常。</p><p>入院初步诊断为“1) 急性胃肠炎伴重度脱水，2) 脓毒症，3) 低钾血症，4) 心肌损伤”，给予静滴“氯化钾”代替治疗、“拉氧头孢钠”抗感染、“西咪替丁”保护胃肠粘膜及常规营养对症支持治疗，治疗1天后患儿未再呕吐，随后多次复查电解质血钾均较正常值低，余血清电解质大致正常(表1)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Serum potassium test results after the child was admitted to the hospita</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >日期</th><th align="center" valign="middle" >4.1日</th><th align="center" valign="middle" >4.2日</th><th align="center" valign="middle" >4.3日</th><th align="center" valign="middle" >4.4日</th><th align="center" valign="middle" >4.5日</th><th align="center" valign="middle" >4.6日</th><th align="center" valign="middle" >4.7日</th></tr></thead><tr><td align="center" valign="middle" >血清钾浓度(mmol/L)</td><td align="center" valign="middle" >1.4</td><td align="center" valign="middle" >1.9</td><td align="center" valign="middle" >2.1</td><td align="center" valign="middle" >2.0</td><td align="center" valign="middle" >6.3</td><td align="center" valign="middle" >2.0</td><td align="center" valign="middle" >1.8</td></tr></tbody></table></table-wrap><p>表1. 患儿入院治疗后血清钾检测结果</p><p>注：参考区间：血钾3.5~5.3 mmol/L。</p><p>入院后经积极补钾、抗感染治疗后，患儿病情明显缓解，但血钾仍低于正常值，笔者考虑遗传代谢方面疾病，遂建议家属进行基因检测分析，采集患者血液标本，送至北京诺禾心康基因科技公司，完善血钾异常疾病相关基因检测，送检后结果示：</p><p>SLC12A3基因c.2782C &gt; T(p.R928C)纯合变异(编码区第2782号核苷酸由胞嘧啶变异为胸腺嘧啶)，导致氨基酸改变p.R928C(第928号氨基酸由精氨酸变异为半胱氨酸)，为错义突变，该突变位点位于NCCT的胞内的羧基端 [<xref ref-type="bibr" rid="hanspub.41854-ref1">1</xref>]。根据美国ACMG指南，该变异初步判定为临床意义未明，疾病表型：Gitelman综合征(图1)。经家系验证分析：赵父该位点杂合变异(图2)，赵母该位点杂合变异(图3)。结合该患儿的临床表现及实验室检查结果为GS表现，且基因检测结果为SLC12A3纯合子突变(图4)，符合孟德尔遗传定律的常染色体隐性遗传。故诊断明确：Gitelman综合征。</p><p>图1. 与患儿临床表型高度相关的变异基因</p><p>图2. 患儿父亲基因测序序列</p><p>图3. 患儿母亲基因测序序列</p><p>图4. 患儿基因测序序列</p></sec><sec id="s7"><title>3. 讨论</title><p>Gitelman综合征是1996年Simon等人 [<xref ref-type="bibr" rid="hanspub.41854-ref2">2</xref>] 从分子遗传学研究中发现的，是由于16号染色体长臂(16q13)的SLC12A3基因突变导致噻嗪类敏感的Na<sup>+</sup>-Cl<sup>−</sup>共转运体(NCCT)功能缺陷引起。NCCT表达于远曲小管(DCT)管腔上皮细胞的顶膜，正常情况下DCT可重吸收7%肾小球滤过的NaCl，当NCCT失活后DCT重吸收NaCl减少，这增加了远曲小管和集合管对Na<sup>+</sup>-K<sup>+</sup>交换及Na<sup>+</sup>-H<sup>+</sup>交换，从而促进了K<sup>+</sup>、H<sup>+</sup>的分泌，引起低钾性碱中毒，同时Cl<sup>−</sup>的丢失也是造成代谢性碱中毒的重要原因 [<xref ref-type="bibr" rid="hanspub.41854-ref3">3</xref>]。其典型临床表现为“五低一高”，即低钾血症、低镁血症、低尿钙症、代谢性碱中毒、高肾素–血管紧张素–醛固酮，但是患者血压正常或偏低。截止2020年，据数据库(http://www.hgdm.cf.ac..uk/ac/index.php)记载，该基因已筛选到大约443个致病突变位点，其中无义突变及错义突变共280种，缺失突变71种，剪接位点突变59种，插入突变32种，复杂的基因重组1种 [<xref ref-type="bibr" rid="hanspub.41854-ref4">4</xref>]。GS患者中绝大部分是复合杂合致病突变，也有一定数量的纯合致病突变，但是也有研究发现一小部分患者仅仅携带一个致病突变位点。根据患者的临床表现及实验室检查结果来诊断GS存在一定的闲难，临床上很多以低血钾为首发表现的GS患者容易被误诊、漏诊，但随着基因检测技术的不断开展，越来越多的低钾血症被诊断为GS，因此基因突变仍是诊断GS的金标准 [<xref ref-type="bibr" rid="hanspub.41854-ref5">5</xref>]，但GS的最终诊断需联合临床表现、生化异常、基因检测综合分析得出 [<xref ref-type="bibr" rid="hanspub.41854-ref6">6</xref>]。</p><p>目前有研究发现GS患者中有一部分血镁正常 [<xref ref-type="bibr" rid="hanspub.41854-ref7">7</xref>]，约20%~40% [<xref ref-type="bibr" rid="hanspub.41854-ref8">8</xref>]，同时也有越来越多研究发现表明低尿钙和低血镁并非GS固有的生化结果。如Nakamura等 [<xref ref-type="bibr" rid="hanspub.41854-ref9">9</xref>] 报道1例Gitelman综合征患者存在正常的血镁水平，无肾性失镁，且临床症状较低血镁的GS患者更轻。而GS中血镁浓度正常可能与髓袢小管受损、低容量刺激醛固酮产生增加，加强镁离子吸收有关 [<xref ref-type="bibr" rid="hanspub.41854-ref10">10</xref>]。且大部分研究显示GS患者大多于青少年或成年发病，目前我国GS的典型病例报道中以成人为主，儿童GS病例数量相对较少，且儿童病例临床特征、发病年龄、生化特点等方面存在较大多样性和非特异性。有报道表明少数患者(&lt;20%)起病早(&lt;6岁)，可在儿童期甚至新生儿期出现部分临床症状，且多为消化、泌尿及神经系统症状，如：呕吐、便秘、遗尿、头晕、共济失调、手足痉挛、抽搐、肌麻痹等。有研究 [<xref ref-type="bibr" rid="hanspub.41854-ref11">11</xref>] 显示，GS的发病年龄最小为出生后即出现临床症状，且发病年龄越小越有可能出现更严重的症状，如：起病早(6岁前)、生长迟缓、身材矮小、发热性惊厥、癫痫、软骨钙质沉着、糖代谢异常和室性心律失常 [<xref ref-type="bibr" rid="hanspub.41854-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.41854-ref13">13</xref>]，大脑炎性假瘤、横纹肌溶解、视力模糊、巩膜脉络膜钙化 [<xref ref-type="bibr" rid="hanspub.41854-ref14">14</xref>]，因此发现其可能并不是一种缓和性疾病。本研究患儿与国内外报道的其他患者相比，其临床表现不典型，以“呕吐及严重的感染”为主要表现，且其中1次血气分析PH值(7.436)处于正常范围内，达不到诊断GS的标准，因此笔者一开始认为该患儿出现低钾血症只是与患儿严重胃肠道表现有关，但经过入院后积极抗感染及补钾治疗后，患儿胃肠道症状消失数天后，其血钾水平不升反降，且血镁、血氯、血钙、血钠均在正常范围内，在结合患儿腹部CT结果也排除了肾上腺等病变，至此才怀疑患儿病情并非单纯的消化系统疾病，患儿严重的低钾血症可能是胃肠道失钾进一步加重了原本的低钾状态。Tseng [<xref ref-type="bibr" rid="hanspub.41854-ref15">15</xref>] 等研究发现纯合子突变的患儿表现为更严重的低钾血症，此患儿住院期间血钾最低值为1.2 mmol/L，而GS的诊断标准为血钾 &lt; 3.5 mmol/L。再次回顾该患儿个人史：实际生活年龄为4岁10个月，体重：11 kg，身高：100 cm，均低于同性别同年龄组儿童的第3百分位，体格发育明显落后于正常同龄儿，已达到“矮小症”的诊断标准，考虑为GS导致的生长发育迟缓，其发病机制尚不清楚。实验研究发现，长期低钾饮食的小鼠，身长明显缩短，体重增加。血清生长激素(GH)和胰岛素样生长因子1 (IGF-1)水平较低 [<xref ref-type="bibr" rid="hanspub.41854-ref16">16</xref>]，这提示缺钾可能影响垂体分泌GH。因此对于GS患儿表现出生长发育迟缓时，应积极完善GH-GFI-1轴检测，必要时予以生长激素代替治疗。举一反三当临床中发现患儿低钾血症，伴身材矮小(或偏矮)，我们应注意对其进行GS筛查 [<xref ref-type="bibr" rid="hanspub.41854-ref17">17</xref>]。此外该患儿长期低钾血症导致了T波改变，更应该定期随访观察，以免引起严重的心脏疾病而危及生命。因此对于发病年龄小，临床表现不典型的患儿，我们在积极治疗疾病本身的同时，应积极关注其出现的其他系统的并发症以便及早干预。</p><p>对于该疾病的治疗，目前尚无根治方法，主要是以减轻症状为主，纠正血清电解质紊乱，具体措施是以食补 + 终身口服或静脉补钾、补镁代替治疗，保钾利尿剂、肾素血管紧张素阻断剂(血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂)和非甾体类抗炎药物等也是临床上会用到的治疗药物，其目的是使GS患者的血钾水平维持在3.0 mmol/Ｌ以上，血镁水平至少达到0.6 mmol/L [<xref ref-type="bibr" rid="hanspub.41854-ref18">18</xref>]，但需要制定个体化方案，因人制宜。然而，这些药物的治疗效果、耐受性、安全性及长期使用的副作用(如心率失常、软骨钙化、慢性肾病、继发性高血压、代谢综合征)的相关证据却由于研究较少而十分有限，因此还需要大量随访观察来研究患者的预后、可能出现的并发症及其生存质量等。</p><p>通过本病例的学习，提示临床医生对于临床表现不典型合并反复低钾血症的患儿，我们应在排除常见病的同时积极考虑GS的可能，对于有条件的病例应尽早完善基因检测，早明确诊断，早积极治疗，早预防可能出现的并发症。由于需要终生服药，部分患儿的依从性较差，我们还应该建立完善的长期随访机制，以便能改善患儿的远期预后，提高生活质量。</p></sec><sec id="s8"><title>文章引用</title><p>王晨阳,冯孝强. 1例儿童Gitelman综合征并矮小症的临床分析Clinical Analysis of a Child with Gitelman Syndrome and Short Stature[J]. 临床医学进展, 2021, 11(04): 1190-1196. https://doi.org/10.12677/ACM.2021.114261</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41854-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">邵乐平. 中国Gitelman综合征患者的基因型表型分析及随访研究[J]. 中华内分泌代谢杂志, 2017, 33(1): 40-46.</mixed-citation></ref><ref id="hanspub.41854-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Gitelman, H.J., Graham, J.B. and Welt, L.G. (1966) A New Familial Disorder Characterized by Hypokalemia and Hypomagnesemia. Transactions of the Association of American Physicians, 79, 221-235.</mixed-citation></ref><ref id="hanspub.41854-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">陈丹丹. 1例SLC12A3基因新突变致Gitelman综合征的家系研究及文献复习[D]: [硕士学位论文]. 南昌: 南昌大学, 2019.</mixed-citation></ref><ref id="hanspub.41854-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Luo, J.W., Yang, X., Liang, J.X., et al. (2015) A Pedigree Analysis of Two Homozygous Mutant Gitelman Syndrome Cases. Endocrine Journal, 62, 29-36. &lt;br&gt;https://doi.org/10.1507/endocrj.EJ14-0289</mixed-citation></ref><ref id="hanspub.41854-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Lu, Q., Zhang, Y., Song, C., et al. (2016) A Novel SLC12A3 Gene Homozygous Mutation of Gitelman Syndrome in an Asian Pedigree and Literature Review. Journal of Endocrinological Investigation, 39, 333-340.  
&lt;br&gt;https://doi.org/10.1007/s40618-015-0371-y</mixed-citation></ref><ref id="hanspub.41854-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Cruz, D.N., Shaer, A.J., Bia, M.J., et al. (2001) Gitelman’s Syndrome Revisited: An Evaluation of Symptoms and Health-Related Quality of Life. Kidney International, 59, 710-717.  
&lt;br&gt;https://doi.org/10.1046/j.1523-1755.2001.059002710.x</mixed-citation></ref><ref id="hanspub.41854-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">章晓芳, 张楚, 俞灵莺. 3例Gitelman综合征患者临床特点和基因突变分析及文献总结[J]. 中华全科医学, 2019, 17(10): 1793-1804.</mixed-citation></ref><ref id="hanspub.41854-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Jiang, L.P., Chen, C., Yuan, T., et al. (2014) Clinical Severity of Gitelman Syndrome Determined by Serum Magnesium. American Journal of Nephrology, 39, 357-366. &lt;br&gt;https://doi.org/10.1159/000360773</mixed-citation></ref><ref id="hanspub.41854-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Nakamura, A., Shimizu, C., Nagai, S., et al. (2010) Problems in Diagnosing Atypical Gitelman’s Syndrome Presenting with Normomagnesaemia. Clinical Endocrinology, 72, 272-276. &lt;br&gt;https://doi.org/10.1111/j.1365-2265.2009.03649.x</mixed-citation></ref><ref id="hanspub.41854-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Lin, S.H., Cheng, N.L., Hsu, Y.J., et al. (2004) Intrafamilial Phenotype Variability in Patients with Gitelman Syndrome Having the Same Mutations in Their Thiazide-Sensitive Sodium/Chloride Cotransporter. American Journal of Kidney Diseases, 43, 304-312. &lt;br&gt;https://doi.org/10.1053/j.ajkd.2003.10.018</mixed-citation></ref><ref id="hanspub.41854-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Nandi, M., Pandey, G. and Sarkar, S. (2015) Gitelman Syndrome in an Infant. Indian Journal of Nephrology, 25, 316.  
&lt;br&gt;https://doi.org/10.4103/0971-4065.156904</mixed-citation></ref><ref id="hanspub.41854-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Riveira-Munoz, E., Chang, Q., Godefroid, N., et al. (2007) Transcriptional and Functional Analyses of SLC12A3 Mutations: New Clues for the Pathogenesis of Gitelman Syndrome. Journal of the American Society of Nephrology, 18, 1271-1283. &lt;br&gt;https://doi.org/10.1681/ASN.2006101095</mixed-citation></ref><ref id="hanspub.41854-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Liu, T., Wang, C., Lu, J., et al. (2016) Genotype/Phenotype Analysis in 67 Chinese Patients with Gitelman’s Syndrome. American Journal of Nephrology, 44, 159-168. &lt;br&gt;https://doi.org/10.1159/000448694</mixed-citation></ref><ref id="hanspub.41854-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">钟芳, 赵家军, 徐潮. Gitelman综合征的家系随访与特征分布[D]: [硕士学位论文]. 济南: 山东大学, 2019.</mixed-citation></ref><ref id="hanspub.41854-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Tseng, M.A., Yang, S.S., Hsu, Y.J., et al. (2012) Genotype, Phenotype, and Follow-Up in Taiwanese Patients with Salt-Losing Tubulopathy Associated with SLC 12A3 Mutation. The Journal of Clinical Endocrinology &amp; Metabolism, 97, E1478-E1482. &lt;br&gt;https://doi.org/10.1210/jc.2012-1707</mixed-citation></ref><ref id="hanspub.41854-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Gil-pena, H., Garcia-Lopez, E., Alvarez-Garcia, O., et al. (2009) Alterations of Growth Plate and Abnormal Insulin-Like Growth Factor I Metabolism in Growth-Retarded Hypokalemic Rats: Effect of Growth Hormone Treatment. American Journal of Physiology-Renal Physiology, 297, 639-654. &lt;br&gt;https://doi.org/10.1152/ajprenal.00188.2009</mixed-citation></ref><ref id="hanspub.41854-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">董倩, 陈晓波, 宋福英, 杜牧, 李国红. 儿童Gitelman综合征临床分析[J]. 中华妇幼临床医学杂志(电子版), 2020, 16(1): 42-49.</mixed-citation></ref><ref id="hanspub.41854-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Blandnard, A., Bockenhauer, D., Bolignano, D., Calo, L.A., Cosyns, E., Devuyst, O., et al. (2017) Gitelman Syndrome: Consensus and Guidance from a Kidney Disease: Improving Global Outcomes (KOIGO) Controversies Conference. Kidney International, 91, 24-33. &lt;br&gt;https://doi.org/10.1016/j.kint.2016.09.046</mixed-citation></ref></ref-list></back></article>